CAPE/PALE salvage chemotherapy for Hodgkin's disease patients relapsing within 1 year of ChlVPP chemotherapy

A. F. Fairey, G. M. Mead, H. W. Jones, J. W. Sweetenham, J. M.A. Whitehouse

Research output: Contribution to journalArticle

7 Scopus citations

Abstract

Background: Patients with advanced Hodgkin's disease failing to achieve complete remission with chemotherapy or developing disease progression within 1 year have a poor prognosis with salvage chemotherapy.Patients and methods: Twenty-five patients fulfilling the above criteria after failing treatment with ChlVPP (chloram-bucil, vinblastine, procarbazine and prednisolone) or its variant were treated with a new salvage regimen CAPE/PALE (cyclophosphamide, adriamycin, prednisolone, etoposideand lomustine), given for 6 courses at three weekly intervals.Results: Thirteen of the 25 patients (52%) achieved complete remission. After a minimum foliow-up period of 38 months five of these patients remained free from disease progression. This regimen was very well tolerated.Conclusions: CAPE/PALE produces results comparable to other salvage regimens in Hodgkin's disease. New strategies are however required for this patient group.

Original languageEnglish (US)
Pages (from-to)857-860
Number of pages4
JournalAnnals of Oncology
Volume4
Issue number10
DOIs
StatePublished - Dec 1993
Externally publishedYes

Keywords

  • Chemotherapy
  • Hodgkin's
  • Salvage

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'CAPE/PALE salvage chemotherapy for Hodgkin's disease patients relapsing within 1 year of ChlVPP chemotherapy'. Together they form a unique fingerprint.

  • Cite this